Form 4: Astera Labs CFO Sells Shares Under 10b5-1 Plan

Astera Labs' Chief Financial Officer, Michael Truett Tate, sold a significant number of shares through a pre-arranged 10b5-1 trading plan.

Summary

• Michael Truett Tate, the Chief Financial Officer of Astera Labs, Inc., executed multiple sales of common stock on December 2nd and 3rd, 2024.
• These sales were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on May 30, 2024.
• The transactions involved the sale of shares held indirectly through the Tate Trust.
• On December 2nd, a total of 167,000 shares were sold at prices ranging from $101.05 to $104.91.
• On December 3rd, a total of 172,566 shares were sold at prices ranging from $105.58 to $117.17.
• The total number of shares sold was 339,566.
• Following these transactions, the Tate Trust's holdings decreased to 1,428,888 shares, with an additional 286,424 shares held directly by Mr. Tate.

Sentiment

Score: 5

Explanation: The document is neutral in sentiment as it reports a routine transaction under a pre-arranged trading plan. While insider sales can sometimes be viewed negatively, the use of a 10b5-1 plan mitigates this concern.

Negatives

• The CFO's sale of a significant number of shares could be perceived negatively by some investors.

Risks

• The market may interpret the CFO's share sales as a lack of confidence in the company's future performance.
• Large sales by insiders can sometimes put downward pressure on the stock price.

Industry Context

This is a routine filing related to insider trading activity. It is common for executives to use 10b5-1 plans to sell shares over time to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the technology sector like Astera Labs.
• Similar filings are regularly made by executives at companies like Nvidia, AMD, and Broadcom, when they execute pre-planned stock sales.
• The volume of shares sold by Mr. Tate is not unusual for a CFO of a company of Astera Labs' size and market capitalization.

Stakeholder Impact

• Shareholders may react to the news of the CFO's share sales, potentially impacting the stock price.

Key Dates

Keywords

Astera Labs, ALAB, Michael Truett Tate, CFO, insider trading, 10b5-1 plan, share sale, Tate Trust